Will Collaboration With Bain Capital Help BMY Advance Its Pipeline?Zacks Investment Research • 07/30/25
Bristol Myers Squibb and Bain Capital Create New Company Dedicated to Developing Innovative Immunology Therapies that Address the Unmet Medical Needs of PatientsBusiness Wire • 07/28/25
Will These 5 Pharma/Biotech Bigwigs Surpass Q2 Earnings Forecasts?Zacks Investment Research • 07/28/25
4 High-Yield Blue-Chip Pharmaceutical Giants Offer Huge Total Return Potential24/7 Wall Street • 07/28/25
Cristian Massacesi, M.D., Joins Bristol Myers Squibb as Executive Vice President, Chief Medical Officer and Head of DevelopmentBusiness Wire • 07/25/25
Bristol Myers Gains 6.3% in a Month: Buy, Sell or Hold the Stock?Zacks Investment Research • 07/24/25
Will Reblozyl Enable BMY to Offset the Impact of Generic Competition?Zacks Investment Research • 07/23/25
Bristol Myers Squibb's Supplemental New Drug Application (sNDA) for Sotyktu (deucravacitinib) for the Treatment of Adults with Active Psoriatic Arthritis Accepted for Review Across Four Regions GloballyBusiness Wire • 07/21/25
Bristol Myers Squibb Announces Topline Results from Phase 3 INDEPENDENCE Trial for Reblozyl® (luspatercept-aamt) in Adult Patients with Myelofibrosis-Associated AnemiaBusiness Wire • 07/18/25
Boomers Get a Big Beautiful Tax Break: 4 Safe Stocks Yielding 5% to Buy Now24/7 Wall Street • 07/18/25
Bristol Myers Squibb, Pfizer to sell blockbuster blood thinner Eliquis at 40% discountCNBC • 07/17/25
Bristol Myers Squibb and Pfizer Announce Direct-to-Patient Eliquis® (apixaban) OptionBusiness Wire • 07/17/25
Bristol-Myers Squibb and Pfizer plan to sell the widely used blood thinner Eliquis directly to patients at a discounted cash priceWSJ • 07/17/25
$7.4 Trillion Is in Money Markets Now: When Rates Fall, These High-Yield Blue Chips Will Run24/7 Wall Street • 07/14/25